Chronic Myelogenous Leukemia (CML) and granulocytosis are closely related because they originate from the bone marrow. They are represented as a result of unregulated and rampant growth of stem cells. The accumulation of the underdeveloped stem cells impairs the functioning of the blood cells resulting in such diseases as cancer. The notable difference between the two diseases is that granulocytosis itself is not an illness but an indication of an underlying condition. It may be a result of blood infection and could also be a symptom of CML; while CML is a type of blood cancer (Campregher 21).
In most instances, CML is preceded by granulocytosis, the reactions of patients with these conditions are fairly the same. Some of common symptoms include increased sweating during sleep, fatigue and regular infections. The severity of the disorders leads to complications in treatment. This is because, the immature stem cells interfere with the production of healthy stem cells and may be deposited in the spleen causing further complications. The treatment routine where granulocytosis is the primary indicator for CML may be chemotherapy, radiation or bone marrow transplant (Campregher 23).
An increase of monocytes count in blood beyond the normal range of 800/mm3 to 1000/mm3, is referred to as monocytosis. Monocytosis and granulocytosis closely compare since both disorders involve the irregular multiplication of the stem cells forming the white blood cells. Increased infections among people with these disorders have been the most common indicator of an underlying condition. This is because white blood cells are part of the immune system and help fight foreign materials in the body. Any disorder in the count or functioning is manifested as blood infection.
Work Cited
Campregher, Paulo. “Standards For The Diagnosis And Treatment Of Chronic Myeloid Leukemia”. Jornal Brasileiro De Patologia E Medicina Laboratorial, vol 54, no. 2, 2018. Web.